124-94-7

• 常用中文名：曲安西龙
• 常用英文名：Triamcinolone
• CAS号：124-94-7
• 分子式：C₂₁H₂₇FO₆
• 分子量：394.434
• 相关类别： 原料药 激素及调节内分泌功能类药 肾上腺皮质激素类药
• 发布时间：2018-05-08 08:00:00
• 更新时间：2024-01-02 19:46:03
• Triamcinolone是合成的长效糖皮质激素。

名称

• 中文名: 曲安西龙
• 英文名: triamcinolone
• 中文别名: 去炎松; 曲安奈德; 9a-氟-11b,16a,17a,21-四羟基-1,4-孕烯-3,20-二酮; 氟羟泼尼松龙
• 英文别名: Aristocort; Cinolone; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; EINECS 204-718-7; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11β,16α)-; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; D1-9a-Fluoro-16a-hydroxyhydrocortisone; MFCD00010477; Triamcinlon; 9α-Fluoro-16α-hydroxyprednisolone; (8S,9R,10S,11S,13S,14S,16R,17S)-9-Fluor-11,16,17-trihydroxy-17-(hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-on; 9a-Fluoro-16a-hydroxyprednisolone; D1-16a-Hydroxy-9a-fluorohydrocortisone; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(hydroxyacétyl)-10,13-diméthyl-6,7,8,9,10,11,12,13,14,15,16,17-dodécahydro-3H-cyclopenta[a]phénanthrén-3-one; 16a-Hydroxy-9a-fluoroprednisolone; Triamcinolone; (11β,16α)-9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16R,17S)-9-Fluoro-17-glycoloyl-11,16,17-trihydroxy-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; Kenalog

物化性质

• 密度: 1.4±0.1 g/cm3
• 沸点: 587.5±50.0 °C at 760 mmHg
• 熔点: 262-263 °C(lit.)
• 分子式: C₂₁H₂₇FO₆
• 分子量: 394.434
• 闪点: 309.1±30.1 °C
• 精确质量: 394.179169
• PSA: 115.06000
• LogP: 0.83
• 外观性状: 白色至灰白色结晶粉末
• 蒸汽压: 0.0±3.7 mmHg at 25°C
• 折射率: 1.618
• 储存条件:

  贮存：室温密封存放

• 稳定性:

  基本性质：肾上腺皮质激素及促肾上腺皮质激素药。 抗炎作用较氢化可的松、泼尼松均强。水钠潴留作用则较轻微。口服易吸收。

• 分子结构:

  1、 摩尔折射率：97.14

  2、 摩尔体积（cm³/mol）：277.3

  3、 等张比容（90.2K）：789.3

  4、 表面张力（dyne/cm）：65.5

  5、 极化率（10-24cm3）：38.51

• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:4

  3.氢键受体数量:7

  4.可旋转化学键数量:2

  5.互变异构体数量:9

  6.拓扑分子极性表面积115

  7.重原子数量:28

  8.表面电荷:0

  9.复杂度:807

  10.同位素原子数量:0

  11.确定原子立构中心数量:8

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

• 更多:

  1.性状：白色或近白色结晶性粉末，无臭，味苦

  2.溶解性：微溶于水，稍溶于乙醇、氯仿、乙醚等

生物活性

• 描述: Triamcinolone是合成的长效糖皮质激素。
• 相关类别:
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 糖皮质激素受体
  研究领域 >> 炎症/免疫
• 参考文献:

  [1]. http://www.drugbank.ca/drugs/DB08908#targets

  [2]. Lung Health Study Research, G., Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med, 2000. 343(26): p. 1902-9.

MSDS

Material Safety Data Sheet Section1. Identification of the substance Product Name: Triamcinolone Synonyms: Section2. Hazards identification Harmful by inhalation, in contact with skin, and if swallowed. H351:Suspected of causing cancer P281:Use personal protective equipment as required Section3. Composition/information on ingredients. Ingredient name:Triamcinolone CAS number:124-94-7 Section4. First aid measures Immediately wash skin with copious amounts of water for at least 15 minutes while removing Skin contact: contaminated clothing and shoes. If irritation persists, seek medical attention. Eye contact:Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical attention. Inhalation:Remove to fresh air. In severe cases or if symptoms persist, seek medical attention. Ingestion:Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention. Section5. Fire fighting measures In the event of a fire involving this material, alone or in combination with other materials, use dry powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus should be worn. Section6. Accidental release measures Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national standards. Respiratory precaution:Wear approved mask/respirator Hand precaution:Wear suitable gloves/gauntlets Skin protection:Wear suitable protective clothing Eye protection:Wear suitable eye protection Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container for disposal. See section 12. Environmental precautions: Do not allow material to enter drains or water courses. Section7. Handling and storage Handling:This product should be handled only by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals, who should take into account the fire, health and chemical hazard data given on this sheet. Storage:Store in closed vessels, refrigerated. Section8. Exposure Controls / Personal protection Engineering Controls: Use only in a chemical fume hood. Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles. General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse. Section9. Physical and chemical properties Not specified Appearance: Boiling point:No data Melting point:No data Flash point:No data Density:No data Molecular formula:C21H27FO6 Molecular weight:394.4 Section10. Stability and reactivity Conditions to avoid: Heat, flames and sparks. Materials to avoid: Oxidizing agents. Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride. Section11. Toxicological information No data. Section12. Ecological information No data. Section13. Disposal consideration Arrange disposal as special waste, by licensed disposal company, in consultation with local waste disposal authority, in accordance with national and regional regulations. Section14. Transportation information Non-harzardous for air and ground transportation. Section15. Regulatory information No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302, or have known CAS numbers that exceed the threshold reporting levels established by SARA Title III, Section 313. SECTION 16 - ADDITIONAL INFORMATION N/A

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : TU3850000 CHEMICAL NAME : Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,16-alpha,17,21-tetrahydroxy- CAS REGISTRY NUMBER : 124-94-7 BEILSTEIN REFERENCE NO. : 2341955 LAST UPDATED : 199710 DATA ITEMS CITED : 20 MOLECULAR FORMULA : C21-H27-F-O6 MOLECULAR WEIGHT : 394.48 WISWESSER LINE NOTATION : L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral SPECIES OBSERVED : Human - woman DOSE/DURATION : 1200 ug/kg TOXIC EFFECTS : Musculoskeletal - other changes TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 99 mg/kg TOXIC EFFECTS : Nutritional and Gross Metabolic - weight loss or decreased weight gain TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >4 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 105 mg/kg/6W-I TOXIC EFFECTS : Kidney, Ureter, Bladder - urine volume increased Blood - other changes Related to Chronic Data - death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 12600 ug/kg SEX/DURATION : female 1-39 week(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1 gm/kg SEX/DURATION : female 4-8 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - abortion TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1 gm/kg SEX/DURATION : female 9-13 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - stillbirth TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 10 mg/kg SEX/DURATION : female 13 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 20 mg/kg SEX/DURATION : female 13 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 100 mg/kg SEX/DURATION : female 8-12 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 10 mg/kg SEX/DURATION : female 11 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 30 mg/kg SEX/DURATION : female 63-65 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 4 mg/kg SEX/DURATION : female 13-16 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 10500 ug/kg SEX/DURATION : female 15-16 week(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - physical TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 2 mg/kg SEX/DURATION : female 11 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) MUTATION DATA TEST SYSTEM : Human DOSE/DURATION : 428 ug/kg REFERENCE : ARDEAC Archives of Dermatology. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.82- 1960- Volume(issue)/page/year: 103,39,1971 *** REVIEWS *** TOXICOLOGY REVIEW AJOGAH American Journal of Obstetrics and Gynecology. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1920- Volume(issue)/page/year: 96,985,1966 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - M2730 No. of Facilities: 174 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 174 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - M2730 No. of Facilities: 98 (estimated) No. of Industries: 1 No. of Occupations: 3 No. of Employees: 2926 (estimated) No. of Female Employees: 2097 (estimated)

安全

• 符号: GHS08
• 信号词: Warning
• 危害声明: H351
• 警示性声明: P280
• 个人防护装备: dust mask type N95 (US);Eyeshields;Gloves
• 危害码 (欧洲): Xn:Harmful
• 风险声明 (欧洲): R40
• 安全声明 (欧洲): S22-S36
• 危险品运输编码: NONH for all modes of transport
• WGK德国: 3
• RTECS号: TU3850000
• 海关编码: 2937229000

合成路线

上下游产品

上游产品  7
2967-24-0 67-78-7 1171-81-9 426-39-1
13951-70-7 23460-76-6 74220-43-2
下游产品  5
76-25-5 3870-07-3 337-02-0 3092-82-8
3924-70-7

海关

海关编码	2937229000